Surveillance of seasonal respiratory viruses among Chilean patients during the COVID-19 pandemic.

Luis A. Alonso-Palomares^{1,3,5*}, C. Joaquín Cáceres⁶, Rodrigo Tapia², Paulina Aguilera-Cortés^{3,5}, Santiago Valenzuela⁴, Fernando Valiente-Echeverría^{1,3,5}, Ricardo Soto-Rifo^{1,3,5}, Aldo Gaggero^{1,4}, and Gonzalo P. Barriga^{1,2#}.

¹ SARS-CoV-2 Research Group, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile.

² Laboratory of Emerging Viruses, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile

³ Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile

⁴ Laboratory of Environmental Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile

⁵ HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile

⁶ Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA

To whom correspondence should be addressed: Dr. Gonzalo Barriga, (gonzalo.barriga@uchile.cl), Emerging Viruses Laboratory, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Independencia 1027, Santiago, Chile

Keywords: Surveillance, respiratory viruses, SARS-CoV-2, Influenza virus, RSV, Rhinovirus

The Study

SARS-CoV-2 has generated over 122 million cases worldwide. Non-pharmaceutical interventions such as confinements and lockdowns started in Chile on March 18th 2020. In Europe, confinements and lockdowns have been accompanied by a decrease in the circulation of other respiratory viruses such as Influenza A virus (IAV), Influenza B virus (IBV) or respiratory syncytial virus (RSV) (1). Although changes in circulation patterns of respiratory viruses have been reported, limited information regarding the southern hemisphere is available where the SARS-CoV-2 pandemic merged with the winter season. We conducted viral surveillance of respiratory viruses and we evaluated their presence and establishing whether they were co-circulating with SARS-CoV-2. Few south hemisphere countries reported the same pattern than Europe where non-pharmaceutical measures began before the winter season (2, 3) but to the best of our knowledge, no report has been generated containing information from Chile. Here, we collected 800 nasopharyngeal-swabs samples (NSS) from 13 health care centers belonging to the north area of Santiago, Chile, between April 1st to July 31st, 2020 (Figure 1). All samples were collected from patients with at least one COVID-19 symptoms. 400 samples were determined as positive for SARS-CoV-2. 64% percent of SARS-CoV-2 positive individuals showed age range between 23-57 years. In addition, women had a significant incidence of positive cases, corresponding to 59% in age range group (Figure 2).

Next, based on geographic location we divided the samples in 3 groups (A, B and C) Figure 1. Location (A) contains the highest number of SARS-CoV-2 cases, contributing more than 50% of the positive samples analyzed in this study (Figure 1). This high positivity could be explained by the population density of location A, which contains at

least 4-fold more inhabitants than locations B and C (Figure 1). Nevertheless, the health centers located in B presented positivity rates higher than 61% for SARS-CoV2 (Table 1), except for sub-locations 9 and 10 (Figure 1), where no positive samples were obtained in the period analyzed. Location C is farthest location from downtown, however, still has a positivity of 54.8% indicating a homogeneous distribution of SARS-CoV-2.

Taken together, our data show a high frequency of positive samples throughout the healthcare centers evaluated suggesting the population density as a risk factor for SARS-CoV-2 transmission since location A and B concentrates more population than location C. These results demonstrate that the 2020 winter season in Santiago presented a high incidence of SARS-CoV-2.

Then, we sought to determine in all samples whether SARS-CoV-2 was co-circulating with other respiratory viruses. We chose predominant respiratory viruses in Santiago (winter season), such as: IAV, IBV, RSV and human rhinovirus (HRV) (Table 1). Adenovirus, Parainfluenza and Metapneumovirus were not evaluated since they are considered all-year viruses (4). The results showed three samples with co-infection between IAV and SARS-CoV-2 (Table 1). This is congruent to recent studies in Ecuador and Brazil showing complete decrease of IAV (5, 6). Despite the co-circulation or co-infection between IAV and SARS-CoV-2 observed, we could not detect RSV or IBV in the SARS-CoV-2 positive samples. These results suggest an impact of the non-pharmaceutical interventions in the circulation of seasonal viruses, as previously reported in Korea and Hong Kong (7, 8). Next, we evaluated the presence of IAV, IBV and RSV in the samples reported as negative for SARS-CoV-2 where five positive samples for IAV and no positive samples for IBV or RSV were detected, suggesting a circulation of these viruses below 1% considering the amount of samples evaluated (Table 1). This is

lower than the information from the northern hemisphere where a range between 2-10% has been reported (9, 10). Taken together, these results suggest a lower co-circulation of IAV with SARS-CoV-2 and co-circulation below the level of detection of this study for SARS-CoV-2 together with IBV or RSV.

Finally, we focused on HRV, responsible for more than 50% of the cold-like illnesses, with a high preponderance to coinfection with other respiratory viral pathogens(11). Furthermore, HRV was the predominant virus after SARS-CoV-2 detected either cocirculating with SARS-CoV-2 or circulating alone(9). The presence of HRV was assessed, showing that 0.25% of the samples were co-infected SARS-CoV-2/HRV. On the other hand, the HRV co-circulation was 0.8% (Table 1). These results establish HRV co-circulation and the co-infection with SARS-CoV-2. Taken together, these results demonstrate the displacement of seasonal respiratory viruses due to the presence of SARS-CoV-2. Despite of this displacement, IAV and HRV are still able to keep cocirculating together with SARS-CoV-2 but to a considerably lesser extent in comparison with previous winter seasons.

Discussion

To gain insights into the potential co-circulation of the most relevant seasonally circulating respiratory viruses together with SARS-CoV-2, a fact on going COVID-19 pandemic was that the vast majority of the SARS-CoV-2 testing during the April-July period was indicated only with the presence of symptoms, we arbitrarily selected 200 samples per month (April to July) for a total of 800 NSS from 13 health care centers located in the north zone of Santiago, Chile.

103 We detected a high positivity rate by health care center between 30,4%-72% and we
 104 observed at least twice co-infections between SARS-CoV-2/IAV or SARS-CoV-2/HRV and
 105 no co-infections with IBV and RSV, which is in agreement with previously reported data
 106 including the southern hemisphere (5,12). Furthermore, IAV and HRV were detected
 107 from negative SARS-CoV-2 samples, whereas no presence of IBV or RSV was obtained
 108 even from the negative SARS-CoV-2 samples (Table 1). These results demonstrate the
 109 displacement of the predominant seasonal respiratory viruses, which have an essential
 110 impact during the winter season caused by the high circulation rate of SARS-CoV-2. A
 111 similar phenomenon was observed after the 2009 Influenza A (H1N1) pandemic, which
 112 generated a decrease of RSV and IAV H3N2 infections (13). The reduction or absence of
 113 IAV, IBV or RSV observed in this study can be explained by the non-pharmaceutical
 114 interventions such as confinement and lockdowns established before the beginning of
 115 the winter season in March 2020. A previous report showed that SARS-CoV-2 could
 116 replace within three weeks the seasonal respiratory viruses circulating (1), while that
 117 HRV co-infections are one of the most commonly observed. However, the impact that
 118 HRV infection co-infecting with other respiratory viruses is still unclear due to
 119 inconsistencies among different studies (11). The effect of HRV in SARS-CoV-2 infection
 120 and the clinical outcome is still unknown.

121 Considering that the vast majority of the SARS-CoV-2 testing during the April-July period
 122 was indicated only with the presence of symptoms, potential bacterial infections or co-
 123 infections cannot be ruled out in this study. The presence of bacterial infections during
 124 the SARS-CoV-2 pandemic has been previously reported (14-16). A previous study
 125 identified *S. Pneumoniae*, *K. pneumoniae* and *H. influenza* among the bacteria

126 cocirculating with SARS-CoV-2 (16). However, the detection of bacteria is beyond the
127 scope of the study

128 In conclusion, the data shows the impact of SARS-CoV-2 over the co-circulation of
129 seasonal respiratory viruses like IAV, IBV, and RSV in Chile. Our results suggest that the
130 emergence of SARS-CoV-2 in addition with different non-pharmaceutical measures
131 adopted worldwide have a detrimental impact on the circulation at least of seasonal
132 respiratory viruses. Furthermore, our data allow us to foresee the circulation of
133 respiratory viruses in the 2021 winter season in the southern hemisphere.

134

Conflict of interest

The authors declare that there are no conflicts of interest associated with this work

Ethical statement

The study described here was approved by the Ethics Committee of the Faculty of Medicine at Universidad de Chile (Project N° 036-2020). The samples were de-identified and not considered as human samples.

Acknowledgments and Funding

The authors are supported by Instituto Antártico Chileno (INACH) RT_35-19 (GB-P), ANID Chile through Fondecyt grants N° 11200228 (GB), 1181656 (AG), 1190156 (RS-R), 1180798 (FV-E); Postdoctoral fellowship N° SECTEI/138/2019 from Mexico City (LA-P). Authors would like to thank the Science, Technology, Knowledge and Innovation Ministry of Chile for articulating and coordinating support from the scientific community. Also, we want to thank the diagnostic group of the University of Chile

Authors contributions.

Conceptualization: LAP, CJC and GB, Data curation: LAP, RT, PA, AG, FV-E and GB, Formal analysis: LAP and GB, Funding acquisition: GB, Investigation: LAP, RT, PA, SV and GB, Methodology: LAP, CJC, FAV-E, AG, RS-R and GB, Project administration: LAP, CJC, FV-E, AG, RS-R and GB.

Supervision: LAP, FAV-E, AG, RS-R and GB, Validation: LAP, CJC, and GB, Visualization: LAP, CJC, and GB, Writing-original & draft: CJC, and GB, Writing-review & editing: LAP, CJC, FAV-E, AG, RS-R and GB, All authors approved the final version of the manuscript. Gonzalo Barriga had full data access to all data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

Transparency statement

Gonzalo Barriga affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained

167 **Data availability statement**

168 The authors confirm that the data supporting the findings of this study and its
169 supplementary materials.

170

References

1. Leuzinger K, Roloff T, Gosert R, Sogaard K, Naegele K, Rentsch K, et al. Epidemiology of SARS-CoV-2 Emergence Amidst Community-Acquired Respiratory Viruses. *J Infect Dis*. 2020 Jul 29.
2. Ortiz-Prado E, Simbana-Rivera K, Barreno LG, Diaz AM, Barreto A, Moyano C, et al. Epidemiological, socio-demographic and clinical features of the early phase of the COVID-19 epidemic in Ecuador. *PLoS Negl Trop Dis*. 2021 Jan;15(1):e0008958.
3. Goes LGB, Zerbinati RM, Tateno AF, de Souza AV, Ebach F, Corman VM, et al. Typical epidemiology of respiratory virus infections in a Brazilian slum. *J Med Virol*. 2020 Aug;92(8):1316-21.
4. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. *Annu Rev Virol*. 2020 Mar 20.
5. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. *J Med Virol*. 2020 Jun 12.
6. Konala VM, Adapa S, Naramala S, Chenna A, Lamichhane S, Garlapati PR, et al. A Case Series of Patients Coinfected With Influenza and COVID-19. *J Investig Med High Impact Case Rep*. 2020 Jan-Dec;8:2324709620934674.
7. Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. *Lancet Public Health*. 2020 May;5(5):e279-e88.
8. Choe YJ, Lee JK. The Impact of Social Distancing on the Transmission of Influenza Virus, South Korea, 2020. *Osong Public Health Res Perspect*. 2020 Jun;11(3):91-2.
9. Nowak MD, Sordillo EM, Gitman MR, Paniz Mondolfi AE. Co-infection in SARS-CoV-2 infected Patients: Where Are Influenza Virus and Rhinovirus/Enterovirus? *J Med Virol*. 2020 Apr 30.
10. Mutnal MB, Arroliga AC, Walker K, Mohammad A, Brigmon MM, Beaver RM, et al. Early trends for SARS-CoV-2 infection in central and north Texas and impact on other circulating respiratory viruses. *J Med Virol*. 2020 May 15.
11. Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. *Clin Microbiol Rev*. 2013 Jan;26(1):135-62.
12. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. *Emerg Infect Dis*. 2020 Jun;26(6):1324-6.
13. Yang L, Chan KH, Suen LK, Chan KP, Wang X, Cao P, et al. Impact of the 2009 H1N1 Pandemic on Age-Specific Epidemic Curves of Other Respiratory Viruses: A Comparison of Pre-Pandemic, Pandemic and Post-Pandemic Periods in a Subtropical City. *PLoS One*. 2015;10(4):e0125447.
14. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clin Microbiol Infect*. 2020 Jul 22.
15. Lehmann CJ, Pho MT, Pittrak D, Ridgway JP, Pettit NN. Community Acquired Co-infection in COVID-19: A Retrospective Observational Experience. *Clin Infect Dis*. 2020 Jul 1.

- 216 16. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory
217 pathogens among COVID-2019 cases. Virus Res. 2020 Aug;285:198005.
218
219

Figure 1: Geographical distribution of the samples analyzed in this study. Distribution of the thirteen-health care center from where the samples were obtained. The figure shows the number of samples by health care center (black number below white circle). Red flag shows health cares center with SARS-CoV-2 positive cases, green flag shows health cares with SARS-CoV-2 negative cases, the human shape indicate population by location (A, B and C).

228 **Table 1.- Co-circulation and co-infection of seasonal respiratory viruses together with**
 229 **SARS-CoV-2 in the Northern area of Santiago, Chile.**

230

Location	Health care center*	SARS-CoV-2	IAV	IBV	RSV	HRV	SARS-CoV-2/ IAV	SARS-CoV-2/ HRV
A	1	82/140 (58.6%)	2/140	0	0	2/140	0	1/140
A	2	43/89 (49.4%)	0	0	0	1/89	0	0
A	3	28/76 (38.4%)	0	0	0	0	0	0
A	4	57/117 (47.9%)	2/117	0	0	0	2/117	0
A	5	9/13 (69.2%)	0	0	0	0	0	0
B	6	87/134 (64.9%)	1/134	0	0	0	0	0
B	7	12/22 (54.56%)	0	0	0	0	0	0
B	8	48/82 (58.5%)	0	0	0	1/82	0	0
B	9	0/28	1/28	0	0	0	0	0
B	10	0/40	1/40	0	0	0	0	0
C	11	9/14 (64.3%)	0	0	0	0	0	0
C	12	7/23 (30.4%)	0	0	0	1/23	0	1/23
C	13	18/25 (72%)	0	0	0	1/40	0	0

231

232 *** This study includes a total cohort of 800 individuals**

233

234

235

236

Figure 2.- Number distribution of COVID-19 cases according to age group and sex. from April 1st to July 31st (2020) at Santiago of Chile. 400 patients are considered positive for SARS-CoV-2; however, three patients did not provide any information about age and gender. In red is shows female gender and in blue is shows male gender. The numbers in the columns indicate SARS-CoV-2 positive cases by month.

Materials and methods

Sample selection

All samples in this study were obtained with nasopharyngeal swabs come from suspected Chilean population infected with SARS-CoV-2 in the north of Santiago de Chile from different health centers (figure 1). The samples were collected in 2 mL of RNA-shield media (GenoSUR) and store at room temperature until its analysis for SARS-CoV-2 detection.

RNA extraction and Identification of respiratory viruses by RT-qPCR

The RNA extraction was made using the Total RNA Purification Kit (Norgen Biotek CORP); following the manufacturing procedure, the RNA was a store at -80°C, which was used to perform RT-qPCR.

All samples were analyzed using a specific primer (Supplementary table 1) for SARS-CoV-2, IAV, IBV, RSV, and HRV. All sequences have been validated, and their use is a typical procedure to detect respiratory viruses from the World Health Organization (WHO). The viral genome detection was made using LightCycler® Multiplex RNA Virus Master (Roche) following the manufacturing procedure. The amplification and analysis plot was made in a QuantStudio3 Real Time PCR System 96 wells (Thermo Fisher Scientific). The HRV and IBV detection was performed by RT-PCR final point using specific primers, the retrotranscription step was made using SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific) and PCR was using GoTaq® DNA polymerase (Promega), the genome of HRV was visualized in agarose – Seakem LE Agarose (LONZA) at 2% applying a voltage of 80 Volts for 30 minutes.

Supplementary Table 1.- Primers Sequence for SARS-CoV-2, IAV, IBV, RSV and HRV

Virus	Forward	Reverse
SARS-CoV-2	5' ATGAGCTTAGTCCTGTTG 3'	5' CTCCTTTGTTGTGTTGT 3'
IAV,	5' GACCRATCCTGTCACCTCTGA C 3'	5' AGGGCATTYTGGACAAAKCGTCTA 3'
IBV,	5' GGAGCAACCAATGCCAC 3'	5' GTKTAGGCGGTCTTGACCAG-3'
RSV	5' AACAGATGTAAGCAGCTCCGTTATC 3'	5'-CGATTTTATTGGATGCTGTACATTT 3'
aHRV	5'CAAGCACTTCTGTTTCCC 3'	5'CACGGACACCCAAAGTAGT 3'